ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
ARDELYX, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.09+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $766.53M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
71.2%
177M of 249M shares
Institutional holders
249
44 new, 34 sold out
Net institutional buying
16M
In Q2 2026
Insider trades, 12 months
1 buys · 78 sales
Net sold $2.36M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Israel A. Englander | 18,043,970 | 7.40% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 16,776,055 | 7.20% | 13G (passive) | Dec 31, 2023 |
| Rubric Capital Management LP | 16,202,700 | 6.56% | 13G (passive) | Jun 30, 2026 |
| Millennium Group Management LLC | 14,200,773 | 5.70% | 13G (passive) amendment | Jun 30, 2026 |
| State Street Corporation | 13,604,307 | 5.50% | 13G (passive) | Mar 31, 2026 |
| Millennium Management LLC | 12,099,947 | 5.10% | 13G (passive) | Jun 17, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ARDX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 23,504,630 | 9.43% | $119.87M | +2,340,498 | 0.00% |
| Rubric Capital Management LP | 16,202,700 | 6.50% | $82.63M | +14,341,804 | 0.76% |
| Millennium Management LLC | 13,900,773 | 5.58% | $70.89M | −3,941,597 | 0.03% |
| State Street Corp | 13,356,128 | 5.36% | $68.12M | −248,179 | 0.00% |
| Vanguard Capital Management LLC | 10,471,494 | 4.20% | $53.40M | +105,982 | 0.00% |
| Nomura Asset Management International Inc. | 9,546,732 | 3.83% | $48.69M | +1,377,363 | 0.07% |
| Vanguard Portfolio Management LLC | 8,026,774 | 3.22% | $40.94M | +1,365,081 | 0.00% |
| Geode Capital Management, LLC | 6,401,736 | 2.57% | $32.66M | +394,281 | 0.00% |
| Jupiter Topco LLC | 5,302,311 | 2.13% | $27.04M | New | 0.01% |
| Two Sigma Investments, LP | 5,209,823 | 2.09% | $26.57M | +935,780 | 0.02% |
| Nuveen, LLC | 3,997,099 | 1.60% | $20.39M | −1,237,584 | 0.00% |
| Goldman Sachs Group Inc | 3,685,034 | 1.48% | $18.79M | +468,824 | 0.00% |
| AIGH Capital Management LLC | 3,200,000 | 1.28% | $16.32M | New | 1.03% |
| Morgan Stanley | 2,389,546 | 0.96% | $12.19M | +680,573 | 0.00% |
| Aqr Capital Management LLC | 2,316,220 | 0.93% | $11.81M | −123,230 | 0.00% |
| Northern Trust Corp | 2,280,143 | 0.92% | $11.63M | +209,096 | 0.00% |
| Rock Springs Capital Management LP | 2,241,769 | 0.90% | $11.43M | −57,704 | 0.56% |
| Charles Schwab Investment Management Inc | 2,211,760 | 0.89% | $11.28M | +97,662 | 0.00% |
| Bank Of America Corp /De/ | 2,163,500 | 0.87% | $11.03M | −173,494 | 0.00% |
| Qube Research & Technologies Ltd | 2,090,675 | 0.84% | $10.66M | −344,873 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 249 | 177M | 71.2% | 44 / 88 | 87 / 34 | 39M | 23M |
| Q1 2026 | 242 | 170M | 68.1% | 50 / 106 | 59 / 32 | 47M | 24M |
| Q4 2025 | 229 | 167M | 67.0% | 37 / 79 | 84 / 26 | 31M | 26M |
| Q3 2025 | 223 | 164M | 65.6% | 40 / 78 | 73 / 20 | 21M | 25M |
| Q2 2025 | 206 | 168M | 67.4% | 30 / 78 | 64 / 43 | 27M | 24M |
| Q1 2025 | 221 | 165M | 66.1% | 43 / 89 | 55 / 33 | 33M | 18M |
| Q4 2024 | 213 | 151M | 60.7% | 46 / 76 | 61 / 34 | 21M | 13M |
| Q3 2024 | 203 | 143M | 57.4% | 30 / 76 | 66 / 22 | 31M | 15M |
| Q2 2024 | 197 | 145M | 58.0% | 42 / 67 | 62 / 33 | 19M | 21M |
| Q1 2024 | 189 | 147M | 58.9% | 54 / 62 | 55 / 26 | 28M | 21M |
| Q4 2023 | 162 | 141M | 56.4% | 38 / 70 | 34 / 25 | 28M | 13M |
| Q3 2023 | 150 | 126M | 50.5% | 31 / 53 | 37 / 25 | 27M | 27M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ARDX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 7,416,791 | 2.98% | $37.83M | 0.35% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 7,404,867 | 2.97% | $37.76M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 6,362,240 | 2.55% | $32.45M | 0.04% | Jun 30, 2026 |
| Nomura Small Cap Core Fund | 6,265,909 | 2.51% | $37.85M | 0.69% | May 29, 2026 |
| Vanguard Extended Market Index Fund | 2,831,265 | 1.14% | $14.44M | 0.01% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 2,696,698 | 1.08% | $13.75M | 0.11% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,670,245 | 1.07% | $13.22M | 0.04% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 2,256,163 | 0.91% | $11.51M | 0.07% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund | 2,174,460 | 0.87% | $11.09M | 0.19% | Jun 30, 2026 |
| Vanguard Explorer Fund | 1,508,019 | 0.61% | $7.46M | 0.03% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 1,257,295 | 0.50% | $7.59M | 0.02% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 1,231,025 | 0.49% | $7.44M | 0.04% | May 31, 2026 |
| Nuveen Quant Small Cap Equity Fund | 1,192,550 | 0.48% | $5.90M | 0.15% | Jul 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,166,243 | 0.47% | $7.04M | 0.03% | May 31, 2026 |
| Invesco Biotechnology & Genome ETF | 1,120,704 | 0.45% | $5.55M | 1.97% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Raab | President & CEO, Director | 1,639,970 | 0.66% | Aug 25, 2026 |
| Eric Duane Foster | Chief Commercial Officer | 409,410 | 0.16% | Aug 25, 2026 |
| John E. Bishop | See Remarks | 317,095 | 0.13% | Aug 25, 2026 |
| Susan Hohenleitner | Chief Financial Officer | 227,520 | 0.09% | Aug 25, 2026 |
| Mike Kelliher | Chief Business Officer | 351,662 | 0.14% | Aug 25, 2026 |
| Joseph James Reilly | See Remarks | 146,964 | 0.06% | Aug 25, 2026 |
| James Parker Brady | Chief Human Resources Officer | 259,090 | 0.10% | Aug 25, 2026 |
| Laura A. Williams | Chief Patient Officer | 371,620 | 0.15% | Aug 25, 2026 |
| Felecia Ettenberg | Chief Legal Officer | 237,000 | 0.10% | Apr 22, 2026 |
| Rajani Dinavahi | Chief Medical Officer | 201,000 | 0.08% | Apr 3, 2026 |
| Elizabeth A. Grammer | See Remarks | 302,866 | 0.12% | Nov 25, 2025 |
| Edward R. Conner | Chief Medical Officer | 302,260 | 0.12% | Oct 17, 2025 |
| Justin A. Renz | Chief Financial Officer | 409,052 | 0.16% | Aug 25, 2025 |
| Robert Blanks | See Remarks | 314,421 | 0.13% | Nov 22, 2024 |
| David P. Rosenbaum | Chief Development Officer | 525,970 | 0.21% | Nov 22, 2024 |
| Merdad Parsey | Director | 83,746 | 0.03% | Jun 18, 2026 |
| Onaiza Cadoret-Manier | Director | 178,156 | 0.07% | Jun 18, 2026 |
| David M. Mott | Director | 9,887,572 | 3.97% | Jun 18, 2026 |
| Richard J. Rodgers | Director | 439,998 | 0.18% | Jun 18, 2026 |
| Muna Bhanji | Director | 163,808 | 0.07% | Jun 18, 2026 |
| William C. Bertrand JR | Director | 303,052 | 0.12% | Jun 18, 2026 |
| Robert B. Bazemore | Director | 68,006 | 0.03% | Jun 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Raab President & CEO, Director | Aug 21, 2026 | Sale | −8,411 | $3.86 | $32.47K | 1,638,970 |
| Michael Raab President & CEO, Director | Aug 21, 2026 | Sale | −15,976 | $3.86 | $61.67K | 1,647,381 |
| Michael Raab President & CEO, Director | Aug 21, 2026 | Sale | −19,178 | $3.86 | $74.03K | 1,619,792 |
| Michael Raab President & CEO, Director | Aug 21, 2026 | Sale | −15,009 | $3.86 | $57.93K | 1,663,357 |
| James Parker Brady Chief Human Resources Officer | Aug 21, 2026 | Sale | −1,976 | $3.86 | $7.63K | 259,090 |
| James Parker Brady Chief Human Resources Officer | Aug 21, 2026 | Sale | −13,160 | $3.86 | $50.80K | 245,930 |
| Joseph James Reilly See Remarks | Aug 21, 2026 | Sale | −2,872 | $3.86 | $11.09K | 146,964 |
| Joseph James Reilly See Remarks | Aug 21, 2026 | Sale | −1,110 | $3.86 | $4.28K | 145,854 |
| Mike Kelliher Chief Business Officer | Aug 21, 2026 | Sale | −2,652 | $3.86 | $10.24K | 351,662 |
| Mike Kelliher Chief Business Officer | Aug 21, 2026 | Sale | −2,002 | $3.86 | $7.73K | 349,660 |
| Mike Kelliher Chief Business Officer | Aug 21, 2026 | Sale | −3,104 | $3.86 | $11.98K | 354,314 |
| Susan Hohenleitner Chief Financial Officer | Aug 21, 2026 | Sale | −1,558 | $3.86 | $6.01K | 227,520 |
| John E. Bishop See Remarks | Aug 21, 2026 | Sale | −2,469 | $3.86 | $9.53K | 317,095 |
| John E. Bishop See Remarks | Aug 21, 2026 | Sale | −17,281 | $3.86 | $66.70K | 319,564 |
| Eric Duane Foster Chief Commercial Officer | Aug 21, 2026 | Sale | −2,575 | $3.86 | $9.94K | 409,410 |
| Eric Duane Foster Chief Commercial Officer | Aug 21, 2026 | Sale | −3,389 | $3.86 | $13.08K | 411,985 |
| Eric Duane Foster Chief Commercial Officer | Aug 21, 2026 | Sale | −2,598 | $3.86 | $10.03K | 415,374 |
| Laura A. Williams Chief Patient Officer | Aug 21, 2026 | Sale | −3,089 | $3.86 | $11.92K | 371,620 |
| Laura A. Williams Chief Patient Officer | Aug 21, 2026 | Sale | −2,430 | $3.86 | $9.38K | 369,190 |
| Laura A. Williams Chief Patient Officer | Aug 21, 2026 | Sale | −1,734 | $3.86 | $6.69K | 367,456 |
| Laura A. Williams Chief Patient Officer | Aug 21, 2026 | Sale | −3,486 | $3.86 | $13.46K | 374,709 |
| Michael Raab President & CEO, Director | Jul 15, 2026 | Option exercise | +20,834 | $0.99 | $20.63K | 1,720,034 |
| Michael Raab President & CEO, Director | Jul 15, 2026 | Sale(10b5-1 plan) | −41,668 | $5.06 | $210.84K | 1,678,366 |
| Laura A. Williams Chief Patient Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −81,898 | $5.99 | $490.57K | 378,195 |
| Laura A. Williams Chief Patient Officer | Jun 18, 2026 | Option exercise | +31,000 | $0.99 | $30.69K | 460,093 |
| Richard J. Rodgers Director | Jun 16, 2026 | Award | +26,455 | – | – | 439,998 |
| Robert B. Bazemore Director | Jun 16, 2026 | Award | +26,455 | – | – | 68,006 |
| William C. Bertrand JR Director | Jun 16, 2026 | Award | +12,345 | – | – | 303,052 |
| William C. Bertrand JR Director | Jun 16, 2026 | Award | +26,455 | – | – | 329,507 |
| Onaiza Cadoret-Manier Director | Jun 16, 2026 | Award | +26,455 | – | – | 178,156 |
| Muna Bhanji Director | Jun 16, 2026 | Award | +26,455 | – | – | 163,808 |
| Merdad Parsey Director | Jun 16, 2026 | Award | +26,455 | – | – | 83,746 |
| David M. Mott Director | Jun 16, 2026 | Award | +20,282 | – | – | 3,323,200 |
| David M. Mott Director | Jun 16, 2026 | Award | +26,455 | – | – | 3,349,655 |
| Michael Raab President & CEO, Director | Jun 15, 2026 | Sale(10b5-1 plan) | −41,666 | $5.67 | $236.25K | 1,699,200 |
| Michael Raab President & CEO, Director | Jun 15, 2026 | Option exercise | +20,833 | $0.99 | $20.62K | 1,740,866 |
| Joseph James Reilly See Remarks | May 21, 2026 | Sale | −1,036 | $6.27 | $6.50K | 149,836 |
| Joseph James Reilly See Remarks | May 21, 2026 | Sale | −2,683 | $6.27 | $16.82K | 149,107 |
| James Parker Brady Chief Human Resources Officer | May 21, 2026 | Sale | −1,846 | $6.27 | $11.57K | 261,066 |
| Susan Hohenleitner Chief Financial Officer | May 21, 2026 | Sale | −1,455 | $6.27 | $9.12K | 229,078 |
| Laura A. Williams Chief Patient Officer | May 21, 2026 | Sale | −2,157 | $6.27 | $13.52K | 432,422 |
| Laura A. Williams Chief Patient Officer | May 21, 2026 | Sale | −1,503 | $6.27 | $9.42K | 434,579 |
| Laura A. Williams Chief Patient Officer | May 21, 2026 | Sale | −1,911 | $6.27 | $11.98K | 430,511 |
| Laura A. Williams Chief Patient Officer | May 21, 2026 | Sale | −1,418 | $6.27 | $8.89K | 429,093 |
| Mike Kelliher Chief Business Officer | May 21, 2026 | Sale | −2,478 | $6.27 | $15.54K | 357,418 |
| Mike Kelliher Chief Business Officer | May 21, 2026 | Sale | −1,870 | $6.27 | $11.72K | 359,896 |
| Mike Kelliher Chief Business Officer | May 21, 2026 | Sale | −2,900 | $6.27 | $18.18K | 361,766 |
| John E. Bishop See Remarks | May 21, 2026 | Sale | −2,306 | $6.27 | $14.46K | 336,845 |
| Michael Raab President & CEO, Director | May 21, 2026 | Sale | −14,933 | $6.27 | $93.63K | 1,759,848 |
| Michael Raab President & CEO, Director | May 21, 2026 | Sale | −7,861 | $6.27 | $49.29K | 1,751,987 |
| Michael Raab President & CEO, Director | May 21, 2026 | Sale | −17,926 | $6.27 | $112.40K | 1,734,061 |
| Michael Raab President & CEO, Director | May 21, 2026 | Sale | −14,028 | $6.27 | $87.96K | 1,720,033 |
| Eric Duane Foster Chief Commercial Officer | May 21, 2026 | Sale | −2,405 | $6.27 | $15.08K | 417,972 |
| Eric Duane Foster Chief Commercial Officer | May 21, 2026 | Sale | −3,166 | $6.27 | $19.85K | 422,804 |
| Eric Duane Foster Chief Commercial Officer | May 21, 2026 | Sale | −2,427 | $6.27 | $15.22K | 420,377 |
| Michael Raab President & CEO, Director | May 15, 2026 | Option exercise | +20,833 | $0.99 | $20.62K | 1,816,447 |
| Michael Raab President & CEO, Director | May 15, 2026 | Sale(10b5-1 plan) | −41,666 | $6.28 | $261.66K | 1,774,781 |
| Michael Raab President & CEO, Director | Apr 15, 2026 | Sale(10b5-1 plan) | −41,668 | $6.29 | $262.09K | 1,795,614 |
| Michael Raab President & CEO, Director | Apr 15, 2026 | Option exercise | +20,834 | $0.99 | $20.63K | 1,837,282 |
| Michael Raab President & CEO, Director | Mar 16, 2026 | Option exercise | +20,833 | $0.99 | $20.62K | 1,856,986 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Susan Hohenleitner Officer | Aug 21, 2026 | 2,650 | $10.68K | Aug 21, 2026 | Vesting of restricted stock units |
| Mike Kelliher Officer | Aug 21, 2026 | 10,500 | $42.32K | Aug 21, 2026 | Vesting of restricted stock units |
| Michael Raab Officer | Aug 21, 2026 | 44,500 | $179.34K | Aug 21, 2026 | Vesting of restricted stock units |
| Eric Duane Foster Officer | Aug 21, 2026 | 11,900 | $47.96K | Aug 21, 2026 | Vesting of restricted stock units |
| Laura A. Williams Officer | Aug 21, 2026 | 10,500 | $42.32K | Aug 21, 2026 | Vesting of restricted stock units |
| Joseph James Reilly Officer | Aug 21, 2026 | 4,700 | $18.94K | Aug 21, 2026 | Vesting of restricted stock units |
| John E. Bishop Officer | Aug 21, 2026 | 25,500 | $102.77K | Aug 21, 2026 | Vesting of restricted stock units |
| James Parker Brady Officer | Aug 21, 2026 | 19,700 | $79.39K | Aug 21, 2026 | Vesting of restricted stock units |
| Williams Laura Officer | Jun 18, 2026 | 81,898 | $478.28K | Jun 18, 2026 | Exercise of Stock Options |
| Michael Raab Officer, Director | Jun 17, 2026 | 41,666 | $236.66K | Jun 15, 2026 | Exercise of Stock Options |
| Raab Michael Director, Officer | Jun 15, 2026 | 125,000 | $711.25K | Jun 15, 2026 | Exercise of Stock Options |
| John E. Bishop Officer | May 19, 2026 | 3,700 | $23.05K | May 19, 2026 | Vesting of restricted stock units |
| Michael Raab Officer | May 19, 2026 | 44,500 | $277.24K | May 19, 2026 | Vesting of restricted stock units |
| Joseph James Reilly Officer | May 19, 2026 | 4,700 | $29.28K | May 19, 2026 | Vesting of restricted stock units |
| Eric Duane Foster Officer | May 19, 2026 | 11,900 | $74.14K | May 19, 2026 | Vesting of restricted stock units |